Quality, compounding, and the Category 2 moment · ~6 min read
The Trusted Path
Compounding follows lists and monographs; Category 2 placed 19 peptides off-limits for 503A pharmacies—sparking political debate and a 2026–2027 review.
Two lanes: approved drugs vs. compounded care
An FDA-approved peptide follows one rulebook; a compounded peptide follows another—and bulk lists gate what can be used.
Licensed compounders can prepare customized medicines from bulk substances that appear on FDA lists or meet monograph standards. That system exists so patients can get tailored doses when a manufactured product isn’t a fit—but it is not a free pass to make anything.
2023 — nineteen peptides moved to Category 2
For those substances, 503A compounding is effectively off the table until the landscape changes.
The FDA cited immunogenicity concerns and lack of robust human trial data for several regenerative peptides. BPC-157 and CJC-1295 are among the names people recognize. The technical trigger often cited alongside policy debates: absence of a USP monograph or equivalent quality anchor for many of these bulk materials.
What happens next
The 2026–2027 PCAC / Bulks List review could rewrite who can make what—worth watching if this space matters to you.
Political figures have publicly criticized the Category 2 placements as overreach; pharmacy associations argue for evidence-based criteria. Whatever your view, the next formal review is the practical fork in the road for legal access through licensed compounders.